MedTrace Logo

One Year Glargine Treatment in CFRD Children and Adolescents

NCT00483769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-06-07

No results posted yet for this study

Summary

Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements

Conditions

Interventions

DRUG

Glargine

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Adriana Franzese, Dr · Federico II University

  • Adriana Franzese, Dr · University of Naples Dept of Pediatrics Regional Cystic Fibrosis Center

  • Adriana Franzese, Dr · Federico II University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2007-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483769 on ClinicalTrials.gov